Presentation
LPS-RPPC offers a personalized service for “a la carte” fabrication of recombinant proteins and their subsequent purification by FPLC chromatography. It also offers scientific advisory in protein-drug conjugation.
Services
Available services include: Experimental design:
- Protein design
- Project viability evaluation
- Protein expression system selection
- Protein expression vectors design
- Protein conjugation strategy design
Recombinant protein production:
- Procaryotic expression system: E.coli.
- Eucaryotic expression system: HEK293F.
Protein purification:
- Affinity chromatography (IMAC, Strep-Tag, GST-Trap)
- Ion exchange chromatography (IEX)
- Size Exclusion Chromatography (SEC)
Protein conjugation:
- Amine-coupling
- Cysteine-coupling
- Sortase A-mediated transpeptidation
Protein characterization:
- SDS-PAGE
- Western-blot
- Dynamic Light Scattering (DLS)
- Multi-Angle Dynamic Light Scattering (MADLS)
- Zeta Potential measurement (ELS)
Responsibles
Contact mail: uunzueta@santpau.
Scientific Responsible / Technical Responsible / Manager Responsible
Experience and Trajectory
Oncogenesis and Antitumoral drugs laboratory (GOA) has huge experience in recombinant protein production in different expression Systems and purification by FPLC chromatography. It also has huge experience in proteins conjugation with antitumoral drugs, therapeutic oligonucleotides and other small molecular weigh molecules such as fluorophores. Ongoing projects:
- CNS2024-154280. CXCR4-Targeted siRNA Therapy against KRAS-driven Colorectal Cancer. (AEI, IP: U.Unzueta).
- FISP/MR2024: Precision nano-immunotherapy against CXCR4+ leukemic stem cells in Acute myeloid leukaemia. (FISP, IP: U. Unzueta).
- PI23/00318: Selective depletion of CXCR4+ colorectal cancer stem cells by targeted inhibition of RNA polymerase II. (ISCIII, IP: U.Unzueta).
- PI20/00400: Site-directed conjugation of smart protein nanomedicines to improve targeted therapy of metastatic colorectal cancer. (ISCIII, IP: U.Unzueta).
- CP19/00028: Improved colorectal cancer therapy by targeting the CXCR4 receptor using functional protein nanoparticles with enhanced cytosolic release. (ISCIII, IP: U.Unzueta).
Some relevant publications of the group are:
- Garcia-Leon A. et al. Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model. BIOMEDICINE & PHARMACOTHERAPY. 192, 118573. 2025.
- Rueda A. et al., Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). SCIENCE CHINA-MATERIALS. 66, 4109-4120. 2023.
- Pallares V. & Unzueta U. et al. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 280, 121258. 2023.
- Pallares V. et al. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. J HEMATOL ONCOL. 13-36. 2020.
- Cespedes MV. et al. Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO MOL MED. 10-10, e8772. 2018.
Equipment
Equipment involved in providing the service:
- Akta Pure 25 M1 (Cytiva)
- Zetasizer Ultra Red (Malvern Panalytical)
- Emulsiflex-C5 cell homogeneizer (Avestin)
